| Title | Amphotericin B lipid complex: treatment of invasive fungal infections in patients refractory to or intolerant of amphotericin B deoxycholate. | | Author(s) | Chandrasekar P | | Institution | Division of Infectious Diseases, Department of Internal Medicine, Wayne State University, Karmanos Cancer Institute, Detroit, MI, USA. | | Source | Ther Clin Risk Manag 2008 Dec; 4(6):1285-94. | | Abstract | Amphotericin B lipid complex (ABLC) was introduced in the late 1990s as a less toxic alternative to amphotericin B (AmB) deoxycholate. ABLC is a safe and effective broad-spectrum drug in the treatment of invasive fungal infections in patients with infection refractory to AmB deoxycholate or in patients intolerant of the same formulation. The drug has not been rigorously evaluated for primary therapy. Recent availability of several newer potent and safe drugs has sharply curtailed the use of potentially nephrotoxic ABLC. However, AmB lipid complex is likely to continue to play a limited albeit significant clinical role in view of the narrow spectrum of activity and significant drug-drug interactions of the newer drugs and emergence of drug-resistant fungi. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 19337435 |
|
